Key terms
About DTIL
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DTIL news
Apr 17
2:15pm ET
Precision BioSciences: Strategic Independence and Promising Gene Editing Pipeline Fuel Buy Rating
Apr 17
9:05am ET
Buy Rating Affirmed for Precision BioSciences Amid Strong Gene Editing Prospects and Upcoming Milestones
Apr 16
5:03pm ET
Precision BioSciences Faces Partnership Termination, Eyes Future
Apr 16
4:17pm ET
Precision announces return of programs, conclusion of collab with Prevail
Apr 04
11:04am ET
iECURE announces FDA clearance of IND application for ECUR-506
Apr 01
10:15am ET
BMO Capital Reaffirms Their Hold Rating on Precision BioSciences (DTIL)
Apr 01
7:19am ET
Precision BioSciences price target raised to $30 from $2 at BTIG
Mar 31
6:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 28
11:05am ET
Buy Rating Affirmed for Precision BioSciences on Promising Gene Editing Prospects and Strong Financials
Mar 28
2:02am ET
Precision Biosciences Battles Delisting Risk: Reverse Split to Rescue Stock Price
Mar 27
5:45pm ET
Buy Rating Affirmed for Precision BioSciences as Milestones in Gene Editing Technology Loom
Mar 27
6:48am ET
Precision BioSciences reports Q4 EPS ($4.06), consensus ($2.05)
Mar 20
12:50pm ET
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Actinium Pharmaceuticals (ATNM)
Mar 06
9:06am ET
Precision BioSciences: iECURE’s gets MHRA approval for CTA app to expand study
Mar 04
10:50am ET
Biotech Alert: Searches spiking for these stocks today
Mar 01
6:40am ET
Precision BioSciences 2.5M share Spot Secondary priced at $16.00
Mar 01
6:31am ET
Precision BioSciences announces $40M offering of common stock, warrants
Feb 29
4:02pm ET
Precision BioSciences announces offering of common stock, warrants
Feb 20
7:20am ET
Precision BioSciences in non-exclusive patent license deal with Caribou
Feb 13
7:50pm ET
Precision BioSciences trading halted, news pending
Feb 13
8:42am ET
Precision BioSciences Executes 1-for-30 Reverse Stock Split
Feb 12
7:11am ET
Precision gets initial $7.5M from TG Therapeutics for azer-cel development
Feb 12
7:11am ET
Precision gets initial $7.5M from TG Therapeutics for azer-cel development
Jan 22
2:14pm ET
Buy Rating for Precision BioSciences: Strategic Alliances and Innovative Gene Editing Program Propel Financial Stability and Therapeutic Advancement
Jan 20
3:04am ET
Precision BioSciences Stockholders Approve Reverse Split
No recent press releases are available for DTIL
DTIL Financials
Key terms
Ad Feedback
DTIL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DTIL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
